Find information on thousands of medical conditions and prescription drugs.

Chronic fatigue immune dysfunction syndrome

Chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME), post-viral fatigue syndrome (PVFS) and various other names, is a syndrome of unknown and possibly multiple etiology, affecting the central nervous system (CNS), immune, and many other systems and organs. Most definitions other than the 1991 UK "Oxford", require a number of features, the most common being severe mental and physical depletion, which according to the 1994 Fukuda definition is "unrelieved by rest", and is usually made worse by even trivial exertion (controversially the Oxford and Fukuda require this to be optional only). more...

C syndrome
Café au lait spot
Calcinosis cutis
Canavan leukodystrophy
Canga's bead symptom
Canine distemper
Carcinoid syndrome
Carcinoma, squamous cell
Cardiac arrest
Carnitine transporter...
Caroli disease
Carpal tunnel syndrome
Carpenter syndrome
Cartilage-hair hypoplasia
Castleman's disease
Cat-scratch disease
CATCH 22 syndrome
Cayler syndrome
CDG syndrome
CDG syndrome type 1A
Celiac sprue
Cenani Lenz syndactylism
Ceramidase deficiency
Cerebellar ataxia
Cerebellar hypoplasia
Cerebral amyloid angiopathy
Cerebral aneurysm
Cerebral cavernous...
Cerebral gigantism
Cerebral palsy
Cerebral thrombosis
Ceroid lipofuscinois,...
Cervical cancer
Chagas disease
Charcot disease
Charcot-Marie-Tooth disease
CHARGE Association
Chediak-Higashi syndrome
Childhood disintegrative...
Chlamydia trachomatis
Cholesterol pneumonia
Chorea (disease)
Chorea acanthocytosis
Choroid plexus cyst
Christmas disease
Chromosome 15q, partial...
Chromosome 15q, trisomy
Chromosome 22,...
Chronic fatigue immune...
Chronic fatigue syndrome
Chronic granulomatous...
Chronic lymphocytic leukemia
Chronic myelogenous leukemia
Chronic obstructive...
Chronic renal failure
Churg-Strauss syndrome
Ciguatera fish poisoning
Cleft lip
Cleft palate
Cloacal exstrophy
Cluster headache
Cockayne's syndrome
Coffin-Lowry syndrome
Color blindness
Colorado tick fever
Combined hyperlipidemia,...
Common cold
Common variable...
Compartment syndrome
Conductive hearing loss
Condyloma acuminatum
Cone dystrophy
Congenital adrenal...
Congenital afibrinogenemia
Congenital diaphragmatic...
Congenital erythropoietic...
Congenital facial diplegia
Congenital hypothyroidism
Congenital ichthyosis
Congenital syphilis
Congenital toxoplasmosis
Congestive heart disease
Conn's syndrome
Constitutional growth delay
Conversion disorder
Cor pulmonale
Cor triatriatum
Cornelia de Lange syndrome
Coronary heart disease
Cortical dysplasia
Corticobasal degeneration
Costello syndrome
Craniodiaphyseal dysplasia
Craniofacial dysostosis
CREST syndrome
Creutzfeldt-Jakob disease
Cri du chat
Cri du chat
Crohn's disease
Crouzon syndrome
Crow-Fukase syndrome
Cushing's syndrome
Cutaneous larva migrans
Cutis verticis gyrata
Cyclic neutropenia
Cyclic vomiting syndrome
Cystic fibrosis
Dilated cardiomyopathy
Hypertrophic cardiomyopathy
Restrictive cardiomyopathy

However patients usually contend that they have many, often severe symptoms which are far more onerous, such as pain, muscle weakness, loss of brain function, hypersensitivity, orthostatic intolerance, immune and in some cases life-threatening cardiac and respiratory problems, and it is these symptoms exacerbated by extremely low stamina that cause greatest suffering, not "fatigue", which more properly describes a normal state of recovery unrelated to pathology. Some cases resolve or improve over time, and where available, treatments bring a degree of improvement to many others.


Originally studied since the late 1930s as an immunological neurological disorder under the medical term "myalgic encephalomyelitis" (ME), CFS has been classified by the World Health Organization (WHO) as a disease of the central nervous system since 1969. In 1992 and early 1993 the terms "post-viral fatigue syndrome" (PVFS) and "chronic fatigue syndrome" (CFS) were added to ME under the exclusive ICD-10 designation of G93.3.


There are a number of different terms which have been at various times identified with this organic neuroimmune disorder.

  • Myalgic encephalomyelitis (ME, "inflammation of the brain and spinal cord with muscle pain") as a disease entity has been recognized and described in the medical literature since 1938, with the seminal paper being that by Wallis in 1957; Sir Donald Acheson's (a former Chief Medical Officer) major review of ME was published in 1959; in 1962 the distinguished neurologist Lord Brain included ME in his textbook of neurology, and in 1978 the Royal Society of Medicine accepted ME as a distinct clinical entity. In 1988 both the UK Department of Health and Social Services and the British Medical Association officially recognized it as a legitimate and potentially distressing disorder. Opponents to the term ME maintain there is no inflammation and that not all patients report muscle pain. United Kingdom and Canadian researchers and patients generally use this term in preference to CFS.
  • Chronic fatigue syndrome (CFS); this name was introduced in 1988 by a group of United States researchers based at the Centers for Disease Control and Prevention, and is used increasingly over other designations, particularly in the United States.
  • Chronic fatigue immune dysfunction syndrome (CFIDS); many people, especially patients in the United States, use the term CFIDS (pronounced ), which was originally an acronym for the above or "Chronic Fatigue & Immune Dysregulation Syndrome". This term was introduced by patients current with the biomedical research in an attempt to reduce the psychiatric stigma attached to "chronic fatigue", as well as the public perception of CFS as a psychiatric syndrome.
  • Post-viral syndrome (PVS or PVFS); this is a related disorder. According to original ME researcher Dr. Melvin Ramsay, "The crucial differentiation between ME and other forms of post-viral fatigue syndrome lies in the striking variability of the symptoms not only in the course of a day but often within the hour. This variability of the intensity of the symptoms is not found in post-viral fatigue states" (Ramsay 1989).
  • Chronic Epstein-Barr virus (CEBV) or Chronic Mononucleosis; the term CEBV was introduced by virologists Dr. Stephen Straus and Dr. Jim Jones in the United States. The Epstein-Barr virus, a neurotropic virus that more commonly causes infectious mononucleosis, was thought by Straus and Jones to be the cause of CFS. Subsequent discovery of the closely related human herpesvirus 6 shifted the direction of biomedical studies, although a vastly expanded and substantial body of published research continues to show active viral infection or reinfection of ME/CFS patients by these two viruses. As these viruses are also found in healthy controls, however, it is uncertain what role they play in CFS.
  • Low Natural Killer cell disease; this name is used widely in Japan. It reflects research showing a reduction in the number of natural killer cells in many CFS patients.
  • Yuppie Flu; this was a factually inaccurate nickname for CFS, first published in a November 1990 Newsweek article. It reflects the belief that CFS mainly affects the affluent ("yuppies"), and implies that it is a form of malingering or burnout. CFS, however, affects people of all races, genders, and social standings, and this nickname is inaccurate and considered offensive by patients. It is likely that this article contributed to the damaging public (and even medical) perception of CFS as a psychiatric or even psychosomatic condition.
  • Uncommonly used terms include Akureyri Disease, Iceland disease (in Iceland), Royal Free disease (after the location of an outbreak), raphe nucleus encephalopathy, and Tapanui flu (after the New Zealand town Tapanui where a doctor who investigated the disease lived).


[List your site here Free!]

Clinically proven treatment for Chronic Fatigue Syndrome RM-10™: the newest breakthrough in immune system enhancement—Part 3 - Medical Journalist
From Townsend Letter for Doctors and Patients, 8/1/02 by Morton Walker

You can overcome generalized tiredness, disabling fatigue or outright exhaustion and restore high-level wellness to the body and mind. One's ability to conquer symptoms and signs of Chronic Fatigue Syndrome (CFS) is proven by a newly completed, randomized, placebo-controlled, double-blind study undertaken in the Commonwealth of Puerto Rico, USA. The naturopathic medical study was conducted by a consortium of MDs and NMDs working together in the Clinical Research Division of the Apostolic School of Natural Medicine, Peoples University of the Americas, in Ponce City, PR.

Author of this impressive study model and protocol for the treatment of CFS and other health problems is the school's medical director and its Chief of Clinical Research, Peter R. Rothschild, MD, PhD. Dr. Rothschild was ably assisted by the investigation's managing director, Jesus Garcia, MD. With colleague input, the two medical scientists ran a 120-day test to observe therapeutic responses to RM-10 [TM] for the reduction of symptoms in chronic fatigue syndrome.

Dr. Rothschild states, "We had highly significant results with the multi-mushroom formula, brandnamed RM-10 [TM]. For affected patients, there was a remarkable percentage of remissions and a quite noticeable improvement in symptomology overall.

"I am so impressed with the preventive value of the food supplement that I had tested, I now take it myself every day," says Dr. Rothschild. "At age 73, I am in perfect health, and RM-10 [TM] along with other Garden of Life formulas, are the only supplemental nutrients I use routinely to keep me that way. My supplementation includes a combination of RM-10 [TM], six caplets daily in divided doses before meals; FYI [TM], one caplet taken three times daily to prevent rheumatoid arthritis and fibromyalgia; Clear Energy [TM], ingested three daily for periodic energy boosts; Primal Defense [TM], dosed at three per day to insure proper intestinal function; and the Male Vitality Formula of Revivall [TM], a dose of six caplets per day. I take nothing else as add-ons to my food supply. The clinical studies I have conducted prove that these supplements are the best nutritional preventatives for me to maintain my good health."

The Clinical Study Criteria Followed by Dr, Rothschild

People suffering from clinically confirmed CFS, who have been shown to be resistant to any conventional forms of therapy were selected to receive the RM-10 [TM] formula. Such components include the ten medicinal mushrooms: Ganoderma lucidum (Reishi), Cordyceps sinensis, Coriolus versicolor, Lentinula endodes (Shiitake), Agaricus blazei, Grifola Frondosa (Maitake), Hericium erinaceus, Poria cocos, Tremella fuciformus, and Polyporus umbellatus. Adjunctive to the mushrooms are certain herbs: Aloe vera and Uncaria tomentosa (Cat's Claw). These ingredients are processed and potentiated by Poten-Zyme[TM], a natural fermentation using beneficial microorganisms and their enzymes to release the active ingredients in herbs and inactive nutrient inhibitors.

The individuals chosen for participation in the study were between 25 and 60 years old, suffering from chronic exhaustion of more than six months' duration, showing an imbalanced immune system, and feeling recurrent random muscle soreness. These sick people must not have been treated previously with tranquilizers, antidepressants, steroids, and/or chemotherapeutic drugs for at least three months before the study's beginning. And they should not have received any prescription medicines for at least three months.

No persons were accepted as participants if they were declared in critical condition by a licensed health practioner or were afflicted with any acute infectious disease, diabetes, cardiovascular illness, renal condition, or some other immediately life-threatening pathology. They were excluded if they responded allergically to any component of RM-10[TM] or were alcoholics or drug addicts. Convalescents of any trauma more recent than three months were not taken into the study.

Over a period of four months (from January 17, 2002 to May 19, 2002), this test was undertaken of RM-10[TM] under the research direction of Dr. Peter Rothschild and with the daily management of Dr. Jesus Garcia. They carried forward a standard, ambulatory, randomized, mono-therapeutic, double-blinded regime on 35 CFS patients with an equivalent control group. Using caplets of RM-10[TM], the test preparation being marketed since June, 2001 by Garden of Life, Inc. of Jupiter, Florida USA, furnished striking therapeutic results for patients.

Objective of the investigators was to determine the palliation or attenuation of chronic fatigue syndrome in both sexes among 35 affected people between ages 25 and 60 years of age. Taken with eight ounces of pure drinking water, three caplets were taken 3 times daily before meals. Each test subject's total daily dosage amounted to 9900 mg of RM-10[TM].

Dr. Julian Kenyon Defines Chronic Fatigue Syndrome

In the November 2001 issue of the Townsend Letter for Doctors & Patients, the renowned clinician, Julian Kenyon, MD, MB, ChB, Medical Director of The Dove Clinic for Integrated Medicine located in Hants, England, defined chronic fatigue syndrome as "...a debilitating disease of increasing social and economic importance" with its prevalence in the United States averaging 50 cases per 100,000 population.

"It is characterized by persistent relapsing fatigue of greater than six months' duration that is not alleviated by rest and is exacerbated by moderate exercise.... Against this background of fatigue," continued Dr. Kenyon, "a range of other manifestations are common, ...muscle and joint pain, sore throat and swollen lymph nodes...brain dysfunction such as poor concentration, light sensitivity, sleep disturbance and migraine attacks.

"Case definition," added Dr. Kenyon, "requires the presence of four symptoms in addition to chronic fatigue and the exclusion of other medical conditions which may present a similar picture." (1)

Summarized Studies Undertaken by Peter R. Rothschild, MD, PhD

In summary of Dr. Rothschild's study on RM-10 [TM], all 70 product-treated or placebo-administered patients were confirmed as diagnosed with CFS. Physicians had rated them by their physical examination results, symptom scores, and various blood workups including test panels for T-cells, B-cells, natural killer cells, immunoglobulin G (IgG), red blood cells, and potassium. Among the mushroom-treated patients, 33 out of the starting 35 finished the four-month-long study. Two had dropped out for unrelated causes. There were 12 males and 21 females (totaling 33).

Of these 33 CFS-treated patients, eight ended the RM-10 [TM] test being totally asymptomatic (33 1/3%), fourteen participants (42%) improved in their symptomology by no less than 60%, and eight (almost 25%) declared themselves as being better by 40%. All ofthe patients who took RM-10 [TM] experienced some results and none worsened. Thus, there was good response among 100% of the treated patients. Among the placebo group, half of the people taking sugar pills had no results and the other half experienced a worsening of symptoms.

For the RM-10 [TM] study, 21 patients noticed definite improvements in their various health difficulties which could be considered immune-related: greater resistance to colds and flu, heightened skin tone, better digestion, and deeper sleep. Also participants felt a reduction of arthritic pain evidenced by a lowering of their uric acid levels.

Laboratory-Recorded Improvements for Test-Subjects

Immuno Globulin Gamma: All test-subjects experienced an increase in their immuno gamma globulin levels; this readout of the blood IgG is among the best indicators of effective immune system functioning. A normal IgG laboratory recording ranges between 572 and 1478 per of blood. By the end of this study, the test-subjects' average IgG had elevated to 695.8, which represented a 74% blood level improvement. Of the 33 abnormally low IgG subjects, 29 became normal once again. (See Illustration 1, the pie graph interpretation of tabulated IgG readings on treated patients in this RM-10[TM] study.)

Killer T-Cells: The laboratory test carried forward by the researchers on Killer T-cells indicated that 16 out of the 33 test subjects showed an abnormally low number of them while 17 had increased levels. This means that all of the CFS patients suffered from a form of immune system imbalance, some of whom had immuno-insufficiency.

The 16 patients showing blood readings of low-numbered Killer T-cells started with an average of 763.4 cells per cubic millimeter ( or [mm.sup.3]), whereas the normal range is from 1100 to 1200 cells/ After taking RM-10[TM] in the Rothschild study, the participants' numbers of Killer T-cells jumped to 1130 per of blood, putting them in the normal range. Every low-ranging test subject moved into the normal range with an average 48% increase in their blood counts of Killer T-cells

Among 17 treated patients who had shown elevated Killer T-cells with an average of 1291.5/, they underwent a reduction down to an average of 1130/ of blood. Thus, none of the participants began this study with their Killer T-cells in the normal range, but 25 out of 33 did become normalized by the study's conclusion.

Even those study participants remaining abnormal in their Killer T-cells by the study's end exhibited a tendency toward normality; consequently, 100% of the test participants experienced a regulation in numbers of Killer T-cells--recognized as an immunological modulation. (See the pie graphs shown in Illustrations 2a, 2b, 2c, 2d, and 2e, which depict an interpretation of tables of Killer T-cells in blood content for the men and women tested with RM-10[TM].)

Red Blood Cells: At the beginning, 25 out of the 33 patients given RM-10 [TM] exhibited low normal levels of RBCs (red blood cells or erythrocytes) which pointed to these people having mild or subclinical anemia. Collectively they averaged a low of 3.57 mios/ of blood. However, after RM-10 [TM] usage, the patients' final RBC average had elevated and remained at the more normal level of 4.5 mios/ One hundred percent of subjects showed an RBC improvement. Their blood's ability to carry oxygen had been normalized. (See Illustrations 3a, 3b, and 3c, which show an interpretation of tables of RBCs for RM-10 [TM]-treated subjects.)

Potassium: A main electrolyte for energy levels, heart function, and other forms of metabolism, potassium (K), was determined for content in the blood of subjects tested with RM-10 [TM]. All of them showed K levels below normal, some being prime candidates for heart attack since they had fallen to less than 2.5 mg per liter (mg/I) of blood. As was found by laboratory examinations, at the beginning of this study the participants averaged 2.55 mg of K per liter. By study's end, they recorded a rise to an average potassium level of 3.89 mg per liter (a 53% increase). The reference range for Kis 3.5 mg/ 1 to 5.3 mg/1. Out of the 33 people abnormal for blood content of K, 27 patients rose to the normal range and six had a tendency toward normal levels. That indicates a potassium electrolyte improvement in 100% of the test-subjects by the regular use of RM-10 [TM]. (See Illustrations 4a and 4b, which depict an interpretation of tables of potassium blood content for all of the individuals treated with RM-10 [TM].)

Conclusion from This Study

From the results reported by Dr. Peter Rothschild's investigation conducted during the winter and spring of 2002, RM-10 [TM] must be considered one of the most promising treatments for overcoming chronic fatigue syndrome. Other studies of RM-10 [TM] are currently being undertaken for determining its use as therapy for additional health problems, including its application as an adjunct in cancer therapy.

It's important to note that RM-10 [TM] should be considered an adaptogen because it has shown itself to markedly reduce the body's physical and mental stress levels. Even more significant, the product's medicinal mushrooms and its other ingredients modulate the immune system. This modulation is illustrated by the current study's participants becoming immunologically normal when half of them had overactive immune systems and the other half were underactive.

A certain set of blood markers known as the Lacto-dehydrogenases (LDH), improved for all of those same 33 patients who were taking RM-10 [TM].

Quoting from his research, Dr. Rothschild advises: "Rationale for the therapeutic efficacy of the RM-10 [TM] formula is based on the neuro-immunomodulatory mechanisms of its components. Not only do they restore the neuron's self-repair abilities, but also [these mushroom components] stimulate their capacity to enhance the number of neuronal dendrites. Such action allows, at least to a great extent, compensation for the already unrecoverable neurons. This action explains RM-10's ability to enhance mental as well as physical functions of the treated patient.

"RM-10[TM] has been shown to enhance natural immunity by enhancing natural killer cell [Killer T-cell], lymphocyte, and macrophage function," Dr. Rothschild continues. "This explains how the RM-10[TM] food supplement produces its therapeutic effects, by normalizing immune system function."

In conclusion, RM-10[TM], used as the sole therapy by patients suffering from Chronic Fatigue Syndrome marked by immune system imbalance and poor blood quality; showed a remarkable ability to reduce symptoms and bring the body and immune system into balance. This task was accomplished without a single observed adverse side effect. RM-10[TM] does not work like a drug; rather, it triggers a cascade of powerful healing responses in the body, making it an effective biological response modifier. Every patient utilizing RM-10[TM] who completed the study showed improvement in energy levels. They experienced a dramatic reduction in fatigue and muscle soreness as well as improved mental and emotional state. Nearly one-third of the participants no longer showed symptoms of Chronic Fatigue Syndrome by study's end. There also seemed to be a trend that suggested a general improvement in metabolism and liver functions within many patients.

"Based on my recent research findings, reports from many colleagues around the world, and my over 50 years' experience in medical practice, I believe RM-10[TM] to be the most extraordinarily powerful formula for general immune system modulation I have ever used. Its ability to provide the body with the tools it needs to rebuild and enhance cellular health is unequaled. In a day when disease is lurking behind every corner, it is more imperative than ever to provide the body with protection from the untoward effects of biological stress that wreak havoc and may lead to degenerative illnesses. RM-10[TM] is a formulation that no physician, and more importantly, no suffering patient should be without," affirms Peter R. Rothschild, MD, PhD.


To receive more information about RM-10[TM], contact the product's exclusive manufacturer/distributor, Garden of Life, Inc., 1449 Jupiter Park Drive, #16, Jupiter, Florida 33458 USA; 800-622-8986 or 561-748-2477; Fax 561-575-5488; website:


(1.) Kenyon, J. A descriptive questionnaire-based study on the use of Biobran ([MGN.sub.3][R]), in chronic fatigue syndrome. Townsend Letter for Doctors & Patients. 220:48-50, November 2001.

COPYRIGHT 2002 The Townsend Letter Group
COPYRIGHT 2002 Gale Group

Return to Chronic fatigue immune dysfunction syndrome
Home Contact Resources Exchange Links ebay